Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Bethesda North Marriott Hotel and Conference Center

Apr 25, 2022 7:00 AM - Apr 27, 2022 12:00 PM

5701 Marinelli Road, , North Bethesda, MD 20852 , USA

DIA/FDA Oligonucleotide-Based Therapeutics Conference

DIA Your Way! Join us live in-person or live from the comfort of your home/office. This event offers two learning avenues depending on your preference!

Session 7 Track 3: Oligonucleotide Delivery

Session Chair(s)

Ramin  Darvari, PhD, MS

Ramin Darvari, PhD, MS

Associate Research Fellow

Pfizer Inc., United States

Rohit  Tiwari, PhD

Rohit Tiwari, PhD

Senior Research Scientist, Global Regulatory Affairs-CMC

Eli Lilly & Company, United States

Efficient delivery of oligonucleotide therapeutics to their intended target organs remains a hot topic for enhanced selectivity beyond the liver. Oligonucleotides conjugated to targeting moieties or encapsulated within nanoparticle modalities have enabled commercialization of drug products by improving the pharmacokinetic and pharmacodynamic properties of oligonucleotide therapeutics. This session will feature some of the advancements in this area along with developmental and chemistry, manufacturing and controls related to regulatory aspects.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Understand the technology landscape for oligonucleotide delivery
  • Recognize the CMC challenges associated with novel Oligonucleotide delivery approaches
  • Learn about developmental and regulatory considerations regarding novel oligonucleotide delivery systems


Adam  Dinerman, PhD

CMC Considerations for Protein-Oligonucleotide Conjugates

Adam Dinerman, PhD

Aro Biotherapeutics, United States

Executive Director, Head of Chemistry, Manufacturing and Controls (CMC)

Ramin  Darvari, PhD, MS

Regulatory Reliance in the Age of Complex Modalities

Ramin Darvari, PhD, MS

Pfizer Inc., United States

Associate Research Fellow

Brian  Dooley, MPharm, MSc


Brian Dooley, MPharm, MSc

European Medicines Agency, Netherlands

Quality Specialist

Rachel  Johns, PhD


Rachel Johns, PhD

Avidity Biosciences, Inc., United States

Senior Director, Analytics and Formulations

Donald  Parsons, PhD


Donald Parsons, PhD

Moderna, United States

Vice President, Early Technical Development and LNP Process Development

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.